Uno Cosentino: "We always keep a very close eye on acquisition targets."
Fort Dodge Animal Health, a division of Wyeth, reported global sales of over $1bn last year, the first time it has reported sales at this level. As the company sets its sights even higher, European managing director Ugo Cosentino and marketing director Dr Gabriel Varga spoke to Animal Pharm about the company's strategy in Europe, Middle East and Africa (EMEA). 
Photo: Fort Dodge Animal Health
Like its parent company, Fort Dodge’s European business saw strong sales growth last year. Revenues were around $250m, a double-digit increase over 2006. The business has ambitious plans for further growth. The European company is not nearly as strong as it could be, says Mr Cosentino. Based on its 2006 sales, Fort Dodge ranks fifth worldwide, but only ninth in Europe. The aim is to grow the business in the EMEA region to be at least on a par with Fort Dodge's global ranking.
The strategy will be based on three elements: growing the core business, launching new products, and acquisitions.
"We always keep a very close eye on acquisition targets," says Mr Cosentino. "It could be local companies, it could be bigger companies, it could be products. Whatever fits with our strategic objectives."
Geographical expansion will play a key role, and Fort Dodge is targeting markets in both western and eastern Europe....
You can read the rest of the interview in Animal Pharm Issue 636.
› Not a subscriber? Subscribe
› Sign up for free trial
› Blog: Down on the Pharm
Email a friend
Digital RSS Feed
